ConductScience.org, home

Paper28960366

Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C.

Mauro E and 15 others. Hepatology, 2018. Cited by 118 papers, by iCite.

Cite this record

ConductScience Library. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. Papers, record 28960366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28960366

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C.
PubMed
Journal
Hepatology
PubMed
Year
2018
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
118
iCite
Relative citation ratio, by iCite
4.75
iCite
Revised in PubMed
2018-10-24
PubMed

Authors16

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mauro EEzequiel
2Crespo GGonzalo
3Montironi CCarla
4Londoño MCMaria-Carlota
5Hernández-Gea VVirginia
6Ruiz PPablo
7Sastre LLydia
8Lombardo JJulissa
9Mariño ZZoehttps://orcid.org/0000-0001-6321-9534
10Díaz AAlba
11Colmenero JJordihttps://orcid.org/0000-0001-6024-8479
12Rimola AAntoni
13Garcia-Pagán JCJuan Carlos
14Brunet MMercé
15Forns XXavier
16Navasa MMiquel

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antiviral AgentsMajor topic
Hepatitis CMajor topic
Hypertension, PortalMajor topic
Liver CirrhosisMajor topic
Sustained Virologic ResponseMajor topic
Aged
Elasticity Imaging Techniques
Female
Follow-Up Studies
Hepacivirus
Humans
Liver
Liver Transplantation
Male
Middle Aged
Portal Pressure
Recurrence
Survival Rate

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in29222930Regression of HCV cirrhosis: Time will tell.https://conductscience.org/library/papers/29222930

Source PubMed

Download CSV of comments and corrections

Cited by63

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 118 citations.

PMIDTitleJournalYearIn PapersSource
42223671Reelin level in serum-derived extracellular vesicles predicts regression of M2BPGi-defined liver fibrosis following hepatitis C virus eradication by direct-acting antiviral agents.J Gastroenterol2026https://conductscience.org/library/papers/42223671PubMed
40824526Future research direction of portal hypertension based on Baveno VII.Chin Med J (Engl)2025https://conductscience.org/library/papers/40824526PubMed
40689145Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease.JHEP Rep2025https://conductscience.org/library/papers/40689145PubMed
40542160Pretreatment serum angiopoietin-2 predicts prognosis and liver functional reserve after successful HCV eradication with sofosbuvir and velpatasvir in patients with HCV-related decompensated cirrhosis.J Gastroenterol2025https://conductscience.org/library/papers/40542160PubMed
40480954Polyacrylamide Hydrogels with Reversibly Photocontrolled Stiffness for 2D Mechanobiology.ACS Appl Mater Interfaces2025https://conductscience.org/library/papers/40480954PubMed
39494583New Scenarios in Liver Transplantation for Hepatocellular Carcinoma.Liver Int2025https://conductscience.org/library/papers/39494583PubMed
39285193Akkermansia muciniphila in the small intestine improves liver fibrosis in a murine liver cirrhosis model.NPJ Biofilms Microbiomes2024https://conductscience.org/library/papers/39285193PubMed
39202325AI Digital Pathology Using qFibrosis Shows Heterogeneity of Fibrosis Regression in Patients with Chronic Hepatitis B and C with Viral Response.Diagnostics (Basel)2024https://conductscience.org/library/papers/39202325PubMed
39159947KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease.Clin Mol Hepatol2024https://conductscience.org/library/papers/39159947PubMed
38792873Non-Invasive Diagnostic Tests for Portal Hypertension in Patients with HBV- and HCV-Related Cirrhosis: A Comprehensive Review.Medicina (Kaunas)2024https://conductscience.org/library/papers/38792873PubMed
38739200MicroRNA-223-3p levels in serum-derived extracellular vesicles predict regression of M2BPGi-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents.J Gastroenterol2024https://conductscience.org/library/papers/38739200PubMed
38606180Gut microbes combined with metabolomics reveal the protective effects of Qijia Rougan decoction against CCl4-induced hepatic fibrosis.Front Pharmacol2024https://conductscience.org/library/papers/38606180PubMed
38605932Noninvasive tests for liver fibrosis in 2024: are there different scales for different diseases?Gastroenterol Rep (Oxf)2024https://conductscience.org/library/papers/38605932PubMed
38203436Hepatitis C Virus and the Host: A Mutual Endurance Leaving Indelible Scars in the Host's Immunity.Int J Mol Sci2023https://conductscience.org/library/papers/38203436PubMed
37955206Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication.Aliment Pharmacol Ther2024https://conductscience.org/library/papers/37955206PubMed
37854023A Comprehensive Review of Liver Allograft Fibrosis and Steatosis: From Cause to Diagnosis.Transplant Direct2023https://conductscience.org/library/papers/37854023PubMed
37795065Implementing Better Standard Instruments for Detecting Cirrhosis in Hepatitis C Patients.Cureus2023https://conductscience.org/library/papers/37795065PubMed
37771878Compensated liver cirrhosis: Natural course and disease-modifying strategies.World J Methodol2023https://conductscience.org/library/papers/37771878PubMed
37763276Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents.Life (Basel)2023https://conductscience.org/library/papers/37763276PubMed
37632072Non-Invasive Measurement of Hepatic Fibrosis by Transient Elastography: A Narrative Review.Viruses2023https://conductscience.org/library/papers/37632072PubMed

See all 63 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28960366

GET https://conductscience.org/api/papers/v1/28960366/cited_by?page=2